• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

How a Hike on Mount Everest to Raise Awareness, Funds for Blood Cancer Forever Changed the Lives of the Participants

by | Oct 10, 2022 | Uncategorized

Source: Cure Today articles In 2018, 18 trekkers completed an awe-inspiring hike of the Himalayan highlands to the doorstep of the world’s tallest mountain, Mount Everest, to raise awareness and funding for multiple myeloma, a type of blood cancer. Three of the...

FDA Panel Votes Against Continued Approval of Pepaxto for Myeloma Subtype

by | Sep 28, 2022 | Uncategorized

Source: Cure Today articles The FDA’s Oncologic Drugs Advisory Committee voted against the continued approval of Pepaxto for pretreated relapsed/refractory myeloma, based on survival data from a clinical trial. Read More

Novel CAR-T effective for most patients with advanced multiple myeloma

by | Sep 28, 2022 | Uncategorized

A chimeric antigen receptor T-cell therapy produced a response rate of 71% among patients with relapsed or refractory multiple myeloma, according to phase 1 study results published in The New England Journal of Medicine.Most patients responded to a single dose of the...

FDA advisory panel votes against drugs for lung cancer, multiple myeloma subgroups

by | Sep 23, 2022 | Uncategorized

The FDA Oncologic Drugs Advisory Committee on Thursday voted against questions regarding the benefits vs. risks of two cancer treatments for which new drug applications have been filed.The panel concluded 9-4 that the current benefits of the oral, irreversible...

Workers exposed to World Trade Center site at greater risk for myeloma precursor disease

by | Sep 6, 2022 | Uncategorized

Emergency response and recovery workers, law enforcement and construction workers who reported to the World Trade Center site after 9/11 had a twofold higher risk for myeloma precursor disease compared with the general population.The study findings, published in Blood...

Sarclisa Delivered Through Under-the-Skin Injection Shows Promise in Patients With Pretreated Myeloma

by | Sep 1, 2022 | Uncategorized

Source: Cure Today articles Delivering Sarclisa via an under-the-skin injection may improve the quality of life of patients with pretreated relapsed, refractory multiple myeloma, according to recent research. Read More
« Older Entries
Next Entries »

Recent Content

  • Talquetamab and Teclistamab Achieve Deep, Durable Responses in Patients With Relapsed, Refractory Multiple Myeloma
  • Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study
  • Fixed-Dose Subcutaneous Sarclisa Combo is Non-Inferior to IV Sarclisa in R/R Myeloma
  • Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma
  • Tunneling nanotubes between bone marrow stromal cells support transmitophagy and resistance to apoptosis in myeloma
  • IVIG Supplementation Reduces Infection Risk in Patients With Multiple Myeloma Receiving Teclistamab
  • Combination induces durable responses in advanced multiple myeloma
  • Patient-reported outcome domains in multiple myeloma randomized controlled trials and association with survival outcomes
  • Peroxiredoxin 6 maintains mitochondrial homeostasis and promotes tumor progression through ROS/JNK/p38 MAPK signaling pathway in multiple myeloma
  • Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT